Literature DB >> 18925386

Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A.

S Inan1, D Y-W Lee, L Y Liu-Chen, A Cowan.   

Abstract

Kappa opioid receptor agonists induce water diuresis in animals and humans. We investigated the effects of s.c. nalfurafine, U50,488H, salvinorin A, and its longer-acting analog, 2-methoxymethyl-salvinorin B (MOM-sal B), on urinary output and sodium excretion over 5 h in euvolemic rats. Nalfurafine (0.005-0.02 mg/kg), U50,488H (0.1-10 mg/kg), and MOM-sal B (0.625-5 mg/kg) induced diuresis dose-dependently. Systemically (0.1-10 mg/kg) or centrally (50 microg, i.c.v.) administered salvinorin A was ineffective. 5'-Guanidinonaltrindole, a kappa receptor antagonist, inhibited nalfurafine- and MOM-sal B-induced diuresis. Nalfurafine and MOM-sal B had no effect on arginine vasopressin levels, measured at 2 h. Tolerance did not develop to the diuresis accompanying subchronic administration of nalfurafine (0.02 mg/kg). On the basis of our work, we (a) promote nalfurafine as a candidate diuretic to relieve water retention and (b) highlight salvinorin A as a kappa agonist that does not cause diuresis, probably because of its short duration of action.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925386     DOI: 10.1007/s00210-008-0358-8

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  40 in total

1.  TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys.

Authors:  T Endoh; A Tajima; N Izumimoto; T Suzuki; A Saitoh; T Suzuki; M Narita; J Kamei; L F Tseng; H Mizoguchi; H Nagase
Journal:  Jpn J Pharmacol       Date:  2001-03

2.  Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.

Authors:  Christopher R McCurdy; Kenneth J Sufka; Grant H Smith; Jason E Warnick; Marcelo J Nieto
Journal:  Pharmacol Biochem Behav       Date:  2006-01-23       Impact factor: 3.533

3.  Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.

Authors:  M Wakelkamp; G Alván; J Gabrielsson; G Paintaud
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

4.  Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs.

Authors:  D P Brooks; M Valente; G Petrone; P D Depalma; M Sbacchi; G D Clarke
Journal:  J Pharmacol Exp Ther       Date:  1997-03       Impact factor: 4.030

5.  Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist.

Authors:  T Endoh; H Matsuura; A Tajima; N Izumimoto; C Tajima; T Suzuki; A Saitoh; T Suzuki; M Narita; L Tseng; H Nagase
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

6.  Role of ADH in ethylketocyclazocine-induced diuresis: studies in the Brattleboro rat.

Authors:  G R Slizgi; J H Ludens
Journal:  Life Sci       Date:  1986-06-30       Impact factor: 5.037

7.  Mechanism of diuretic action of U-62,066E, a kappa opioid receptor agonist.

Authors:  K Yamada; M Imai; S Yoshida
Journal:  Eur J Pharmacol       Date:  1989-01-31       Impact factor: 4.432

8.  Differential cardiovascular and renal responses produced by microinjection of the {kappa}-opioid U-50488H [(trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzene-acetamide) methane sulfonate] into subregions of the paraventricular nucleus.

Authors:  Helmut B Gottlieb; Kurt J Varner; Velga A Kenigs; Antonio M Cabral; Daniel R Kapusta
Journal:  J Pharmacol Exp Ther       Date:  2004-09-20       Impact factor: 4.030

9.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

10.  Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.

Authors:  Tomohiko Suzuki; Naoki Izumimoto; Yuko Takezawa; Morihiro Fujimura; Yuko Togashi; Hiroshi Nagase; Toshiaki Tanaka; Takashi Endoh
Journal:  Brain Res       Date:  2004-01-09       Impact factor: 3.252

View more
  10 in total

1.  The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats.

Authors:  Aashish S Morani; Amy Ewald; Katherine M Prevatt-Smith; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

2.  Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.

Authors:  Yan Zhou; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2019-08-27       Impact factor: 3.252

3.  Activation of the opioid μ1, but not δ or κ, receptors is required for nicotine reinforcement in a rat model of drug self-administration.

Authors:  Xiu Liu; Courtney Jernigan
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-20       Impact factor: 5.067

4.  Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.

Authors:  Yan Zhou; Mary Jeanne Kreek
Journal:  Alcohol Clin Exp Res       Date:  2019-05-02       Impact factor: 3.455

5.  Kappa Opioid Receptor Agonist and Brain Ischemia.

Authors:  Chen Chunhua; Xi Chunhua; Sugita Megumi; Liu Renyu
Journal:  Transl Perioper Pain Med       Date:  2014

6.  Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics.

Authors:  Jacob K Meariman; Jane C Sutphen; Juan Gao; Daniel R Kapusta
Journal:  Hypertension       Date:  2021-12-02       Impact factor: 10.190

7.  Inhibition of P2X7 receptors by Lu AF27139 diminishes colonic hypersensitivity and CNS prostanoid levels in a rat model of visceral pain.

Authors:  Roland G W Staal; Adarsh Gandhi; Hua Zhou; Manuel Cajina; Anne-Marie Jacobsen; Sara Hestehave; Allen Hopper; Suresh Poda; Gamini Chandresana; Stevin H Zorn; Brian Campbell; Marta Segerdahl; Thomas Mӧller; Gordon Munro
Journal:  Purinergic Signal       Date:  2022-08-24       Impact factor: 3.950

8.  Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.

Authors:  S Inan; N J Dun; A Cowan
Journal:  Neuroscience       Date:  2009-06-10       Impact factor: 3.590

9.  Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.

Authors:  Yan Zhou; Kevin Freeman; Vincent Setola; Danni Cao; Shane Kaski; Mary Jeanne Kreek; Lee-Yuan Liu-Chen
Journal:  Handb Exp Pharmacol       Date:  2022

10.  Exploring the neurobiology of the premonitory phase of migraine preclinically - a role for hypothalamic kappa opioid receptors?

Authors:  Caroline M Kopruszinski; Robson Vizin; Moe Watanabe; Ashley L Martinez; Luiz Henrique Moreira de Souza; David W Dodick; Frank Porreca; Edita Navratilova
Journal:  J Headache Pain       Date:  2022-09-30       Impact factor: 8.588

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.